Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2025; 13(14): 100262
Published online May 16, 2025. doi: 10.12998/wjcc.v13.i14.100262
Published online May 16, 2025. doi: 10.12998/wjcc.v13.i14.100262
Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management
Xiao-Peng Fu, College of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, Fujian Province, China
Author contributions: Fu XP was responsible for the design of the study, writing the manuscript, revising the manuscript, and approving the final version; Fu XP agrees to be accountable for all aspects of the work.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Peng Fu, College of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, No. 1 Qiuyang Road, Fuzhou 350122, Fujian Province, China. 1220105011@fjtcm.edu.cn
Received: August 11, 2024
Revised: December 22, 2024
Accepted: December 30, 2024
Published online: May 16, 2025
Processing time: 156 Days and 11.4 Hours
Revised: December 22, 2024
Accepted: December 30, 2024
Published online: May 16, 2025
Processing time: 156 Days and 11.4 Hours
Core Tip
Core Tip: This article explores the dual benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in managing hyperuricemia and gout, particularly in patients with type 2 diabetes and cardiovascular complications. By highlighting the ability of SGLT2 inhibitors to lower uric acid levels and reduce the risk of gout flare-ups, this article provides insights into their potential as a comprehensive treatment option. The review also emphasizes the importance of understanding the underlying mechanisms, offering a new perspective on optimizing the clinical application of SGLT2 inhibitors in high-risk patients.